Medtide Inc. (HKG:3880)

Hong Kong · Delayed Price · Currency is HKD

22.66

+0.08 (0.35%)

Jul 31, 2026, 3:54 PM HKT

-35.90% (1Y)

Market Cap	3.19B -36.3%
Revenue (ttm)	634.40M +28.9%
Net Income	241.89M +267.3%
EPS	1.81 +332.1%
Shares Out	141.80M
PE Ratio	12.43
Forward PE	10.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,100
Open	22.52
Previous Close	22.58
Day's Range	22.34 - 23.18
52-Week Range	19.00 - 41.72
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2020

Employees 566

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 3880

Full Company Profile

Financial Performance

In 2025, Medtide's revenue was 570.09 million, an increase of 28.91% compared to the previous year's 442.23 million. Earnings were 217.37 million, an increase of 267.35%.

Financial numbers in CNY Financial Statements